A new analysis of the TRITON-TIMI 38 study evaluated response rates in patients with a common genetic variant in the ABCB1 gene. Patients enrolled in the TRITON-TIMI 38 study were treated with dual antiplatelet therapy with either Plavix® (clopidogrel) plus aspirin or Effient® (prasugrel) plus aspirin and managed with percutaneous coronary intervention (PCI) following an acute coronary syndrome …
Adamas Pharmaceuticals, Inc., a privately held company, announced today results from in vivo animal studies and in vitro tests demonstrating that its triple combination antiviral drug (TCAD) therapy is superior relative to double combinations and monotherapy against multiple strains of pandemic and avian influenza viruses. Results of these studies were presented Sunday evening in an oral session …
A new analysis of the TRITON-TIMI 38 study evaluated response rates in patients with a common genetic variant in the ABCB1 gene. Patients enrolled in the TRITON-TIMI 38 study were treated with dual antiplatelet therapy with either Plavix® plus aspirin or Effient® plus aspirin and managed with percutaneous coronary intervention following an acute coronary syndrome event. The results of this …
Adamas Pharmaceuticals, Inc., a privately held company, announced today results from in vivo animal studies and in vitro tests demonstrating that its triple combination antiviral drug therapy is superior relative to double combinations and monotherapy against multiple strains of pandemic and avian influenza viruses.
SUNDAY, March 14 (HealthDay News) — A new drug called mipomersen reduced low-density lipoprotein (LDL) “bad” cholesterol by nearly 25 percent when added to current therapy in people with a rare genetic condition that causes extremely high cholesterol, a new study finds.
March 12 (Bloomberg) — Genzyme Corp. ’s investment arm, Third Rock Ventures of Boston and three other venture capital firms are putting $35 million into closely held Genetix Pharmaceuticals, a gene therapy developer whose technology saved the lives of two French boys with a rare brain disease.
March 12 (Bloomberg) — Genzyme Inc. ’s investment arm and Third Rock Ventures , a Boston venture capital firm, are putting $35 million into closely held Genetix Pharmaceuticals, a gene therapy developer whose technology saved the lives of two French boys with a rare brain disease last year.
Genetix Pharmaceuticals, a leading gene therapy company developing breakthrough treatments for severe genetic disorders, announced today the appointment of Mitchell Finer, Ph.D. as Chief Scientific Officer.
Genetix Pharmaceuticals, a leading gene therapy company developing breakthrough treatments for severe genetic disorders, announced today that it has completed a $35 million Series B financing with new investors Third Rock Ventures and Genzyme Ventures joining TVM Capital, Forbion and Easton Capital.
Genetix Pharmaceuticals, a leading gene therapy company developing breakthrough treatments for severe genetic disorders, announced today that it has completed a $35 million Series B financing with new investors Third Rock Ventures and Genzyme Ventures joining TVM Capital, Forbion and Easton Capital. Proceeds from the financing will be used to advance current clinical programs, strengthen …
Azur Pharma Limited today announced it has signed a definitive agreement with Elan Pharmaceuticals, Inc. (a subsidiary of Elan Corporation, plc) to acquire the analgesic therapy, PRIALT(R) (ziconotide intrathecal infusion).
Shahriar Koochekpour, MD, PhD, Assistant Professor of Microbiology and Immunology, Biochemistry and Molecular Biology, and Genetics at LSU Health Sciences Center New Orleans, led research that has discovered, for the first time, a genetic mutation in African-American men with a family history of prostate cancer who are at increased risk for the disease.
Researchers from four laboratories that perform diagnostic genetic testing of chromosome abnormalities in individuals with unexplained physical and developmental disabilities recently identified a previously unrecognized genetic disorder…
Tears in the shoulder’s rotator cuff, a common sports injury, are painful and restricting. Surgery to repair the damage is successful for pain management, but in many patients it does not result in full recovery of function due to poor healing. New research shows an approved therapy for osteoporosis, Forteo, may speed healing and improve patient outcomes.
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today that the first patient has been dosed in the Phase I/II exploratory clinical trial with a gene therapy product for hemophilia B, a seriously debilitating and potentially lethal disease.
Researchers from four laboratories that perform diagnostic genetic testing of chromosome abnormalities in individuals with unexplained physical and developmental disabilities recently identified a previously unrecognized genetic disorder.
Using newly affordable technology, researchers at the University of Utah and other institutions have sequenced for the first time the entire genome of a family.
SPOKANE, Wash.—-Researchers from four laboratories that perform diagnostic genetic testing of chromosome abnormalities in individuals with unexplained physical and developmental disabilities recently identified a previously unrecognized genetic disorder.
They were blessed with a daughter, Ng Xin Yuen, in 2007 but that was also when their heartache and nightmare began. “She looked like a perfectly healthy baby when she was born. But when she was 3 mont…
A single session of heat therapy using the ThermoMed device appears to be as effective as a 10-day intravenous course of sodium stibogluconate (Pentostam) for the treatment of Leishmania major skin lesions, according to a new study by Naomi Aronson and her colleagues at the Uniformed Services University of the Health Sciences and Walter Reed Army Medical Center (WRAMC).
For 25 years, scientists have touted the promise of gene therapy to treat human diseases, but only a handful of therapies have shown progress. Nonetheless, proponents remain optimistic and say the approach may yet revolutionize medicine.
Dr. Marc McKee, of McGill’s Faculty of Dentistry and the Department of Anatomy and Cell Biology, is collaborating closely with Enobia Pharma Inc, a Quebec biotech company, to develop innovative treatments for serious genetic bone diseases. McKee’s research looks into the reasons why calcium-phosphate mineral fails to crystallize properly to form strong bones and teeth. While osteoporosis later …
March 5 (Bloomberg) — CSL Ltd., the world’s second-biggest maker of treatments derived from blood, won U.S. clearance to sell a weekly immune-replacement therapy for people with genetic disorders that lead to frequent infections.
March 4 (Bloomberg) — CSL Ltd. won U.S. clearance to sell a weekly immune-replacement therapy for people with genetic disorders that cause frequent infections.
March 5 (Bloomberg) — CSL Ltd. in Australian trading rose to the highest in more than a year after it won U.S. clearance to sell a weekly immune-replacement therapy for people with genetic disorders that lead to frequent infections.